Regeneron Pharmaceuticals

Yahoo Finance • 2 months ago

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Morgan Stanley Overweight & Quality Stock?

We recently made a list of Morgan Stanley’s Best Overweight & Quality Stocks: Top 25 Stocks. In this piece, we will look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks on the list of the top overweight and quality stocks. Th... Full story

Yahoo Finance • 2 months ago

Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?

We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ranks among the best NASDAQ stocks under $5. Job Market Cools Yet Economists Remain Optimistic... Full story

Yahoo Finance • 2 months ago

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab... Full story

Yahoo Finance • 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN): The Best Biotech Stock According to Hedge Funds?

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds.In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other biotech stocks. A... Full story

Yahoo Finance • 3 months ago

Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030

Is Cathie Wood a genius investor? The CEO of Ark Invest, an investment management firm, rose in prominence in the early days of the pandemic; her firm's actively managed ETFs performed well even as the rest of the market was moving in the... Full story

Yahoo Finance • 3 months ago

Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Pharmaceuticals, Inc. Approval of Ordspono is based on data demonstrating robust and durable responses in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, including in the post-CAR-T setting Ordsp... Full story

Yahoo Finance • 3 months ago

Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year earnings growth trails the incredible shareholder returns

Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly amazing gains over the years. For example, the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) share price is up a whopping... Full story

Yahoo Finance • 5 months ago

3 No-Brainer Stocks to Buy in July

July is for barbecues, fireworks, and vacations. Many people don't want to think too hard about anything. Three Fool.com contributors think they have solutions for those investors who don't want to think too hard. Here's why they picked E... Full story

Yahoo Finance • 5 months ago

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontr... Full story

Yahoo Finance • 5 months ago

Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only treatm... Full story

Yahoo Finance • 5 months ago

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Sanofi - Aventis Groupe Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved hi... Full story

Yahoo Finance • 6 months ago

Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance A Reflection Of Its Financial Health?

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s fundamentals to see if they could be influencing the... Full story

Yahoo Finance • 6 months ago

Stock Split Watch: 3 Growth Stocks That Could Be Next

Stock splits are back in style. Over the past few months, both fast-casual chain Chipotle and chip giant Nvidia announced plans to split their stocks. There's no knowing for sure if more such announcements are on the horizon -- but shares... Full story

Yahoo Finance • 6 months ago

The Biggest Publicly Traded Biotech Company

In this article, we will be discussing the biggest publicly traded biotech company that ranks at the top of our free list of the 20 Biggest Publicly Traded Biotech Companies. Biotechnology and Industry 2023: Market Growth, Transformations... Full story

Yahoo Finance • 9 months ago

20 Fastest Growing Biotech Companies in the US

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In Th... Full story

Yahoo Finance • 9 months ago

2 Top Growth Stocks to Buy With $1,000 Right Now

The healthcare industry has proved to be a remarkably resilient place for investors. Generally speaking, the kinds of products and services that companies in this space offer are required on a consistent basis. As a result, these businesse... Full story

Yahoo Finance • 9 months ago

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

Many Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insiders are buying is usually more helpful when evaluating insider... Full story

Yahoo Finance • 9 months ago

16 Most Advanced Countries in Medicine

In this article, we list and discuss the 16 Most Advanced Countries in Medicine. If you would like to skip our detailed discussion of the medicine and pharmaceutical industry, you can go directly to 5 Most Advanced Countries in Medicine.... Full story

Yahoo Finance • 9 months ago

30 Most Valuable Drug Companies in 2024

In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global P... Full story

Yahoo Finance • 10 months ago

Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 42%?

Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,612 based on 2 Stage Free Cash Flow to Equity Regeneron Pharmaceuticals is estimated to be 42% undervalued based on current share price of US$938 Our fair value e... Full story